Exercise for Parkinson Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Parkinson Disease
Exercise - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will offer a community and group-based exercise program for participants with Parkinson's and their care partners.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 17 Secondary · Reporting Duration: Prior to exercise intervention (T1), after 3 months of intervention (T2), and after 6 months of exercise intervention (T3)

Month 6
Participant Attendance
Month 6
Change in Global Rating of Change at 6 Months
Participant Retention
Month 6
Change in 6 Minute Walk Test at 6 months
Change in Activities Specific Balance Confidence (ABC) Scale at 6 months
Change in Mini Balance Evaluation Systems Test (Mini BESTest) at 6 months
Change in Movement Disorder Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at 6 months
Change in Parkinson's Disease Questionnaire - 39 (PDQ-39) at 6 months
Change in Rand 36-Item Health Survey at 6 months
Change in Self efficacy for exercise scale at 6 months
Change in Self-Reported Physical Activity Level at 6 Months
Change in Social Support for Exercise Scale at 6 months
Change in accelerometer-measured moderate-to-vigorous physical activity at 6 months
Gait
Change in fast-paced gait speed at 6 months
Change in grip strength at 6 months
Change in lower extremity functional strength at 6 months
Throughout the 6-month study period
Participant Recruitment Rate

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Exercise
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Exercise · No Placebo Group · N/A

Exercise
Behavioral
Experimental Group · 1 Intervention: Exercise · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exercise
2016
Completed Phase 1
~760

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: prior to exercise intervention (t1), after 3 months of intervention (t2), and after 6 months of exercise intervention (t3)

Who is running the clinical trial?

Arkansas Colleges of Health EducationLead Sponsor
4 Previous Clinical Trials
1,128 Total Patients Enrolled
Reed Handlery, PhDPrincipal InvestigatorArkansas Colleges of Health Education

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be at least 18 years of age.
You are a self-identified care partner of a person with Parkinson's participating in the study.
Participants must be able to ambulate independently and/or propel a power or manual wheelchair independently.
You are a care partner of someone with Parkinson's.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: October 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References